United States - English - NLM (National Library of Medicine)

avkare - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq), amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - telmisartan 40 mg - telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin ii receptor blockers and dihydropyridine calcium channel blockers. there are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high bloo

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - telmisartan 40 mg - telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committ

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - hydrochlorothiazide,telmisartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - hydrochlorothiazide,telmisartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - hydrochlorothiazide,telmisartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, multilayer - excipient ingredients: sodium starch glycollate type a; meglumine; lactose monohydrate; sodium hydroxide; maize starch; microcrystalline cellulose; mannitol; magnesium stearate; povidone; iron oxide red - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 25 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: microcrystalline cellulose; sodium hydroxide; maize starch; magnesium stearate; povidone; sodium starch glycollate type a; lactose monohydrate; meglumine; mannitol; iron oxide yellow - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: lactose monohydrate; mannitol; maize starch; sodium starch glycollate type a; povidone; magnesium stearate; sodium hydroxide; meglumine; microcrystalline cellulose; iron oxide red - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq) - telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq) - telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of